

BEYOND 2020:

Targeting EGFR Exon 19 and Exon 21 L858R in the New Era

21 November 2020 | 12:00–13:30 (SGT) | Channel 3

Live Panel Discussion: 12:50–13:20 (SGT)

FACULTY



Ross Soo

Senior Consultant
Department of Haematology-Oncology
National University Cancer Institute
Singapore



Yi-Long Wu

Professor
Guangdong Lung Cancer Institute
Guangdong Provincial People's Hospital
Guangdong, China



Ullas Batra

Chief of Thoracic Medical Oncology
Rajiv Gandhi Cancer Institute &
Research Centre
New Delhi, India



Nellie Cheah

Consultant Oncologist & Radiotherapist
Loh Guan Lye Specialist Centre
Penang, Malaysia

PROGRAM

DURATION	TOPIC	FACULTY
10 min	Opening remarks and introduction	Ross Soo (Singapore)
25 min	Dissecting the molecular differences and clinical outcomes of EGFR patients with exon 19 deletion and exon 21 L858R mutations	Yi-Long Wu (China)
15 min	Case-based discussion	Ullas Batra (India)
30 min	Panel discussion	Ross Soo (Singapore), Yi-Long Wu (China), Ullas Batra (India), Nellie Cheah (Malaysia)
10 min	Concluding remarks	Ross Soo (Singapore)

